SCH 52365 [Temozolomide] Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2017
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Merck & Co
- 21 Feb 2013 Trial company changed from Schering-Plough to Merck and Co as reported by ClinicalTrials.gov.
- 12 Jun 2008 New trial record.